×
About 332,114 results

Pralsetinib Shows Clinical Activity in Multiple RET Fusion–Positive Tumors
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200186/full/

May 28th, 2020 - The investigational RET inhibitor pralsetinib (BLU-667) has demonstrated durable activity, regardless of RET fusion genotype, in multiple advanced solid tumor types, according to data from the phase I/II ARROW trial (Abstract 109). Earlier analyses showed a treatment effect in the phase II cohorts with RET fusion–positive non–small cell lung cancer and RET mutation–positive medullary thyroid ca...

Hepatocellular Carcinoma - A Review
https://www.nejm.org/doi/10.1056/NEJMra1713263?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub 0pubmed
New England Journal of Medicine; Villanueva A

Apr 10th, 2019 - Primary liver cancer is the fourth most common tumor worldwide. Hepatocellular carcinoma occurs mainly in the context of cirrhosis, hepatitis B or C virus infection, or nonalcoholic steatohepatitis. Underlying liver disease limits therapeutic efficacy.

Neuroblastoma Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq?cid=eb_govdel

Neuroblastoma is the most common extracranial solid tumor in childhood. More than 650 cases are diagnosed each year in the United States.[4,5] The prevalence is about 1 case per 7,000 live births; the incidence is about 10.54 cases per 1 million per year in children younger than 15 years.

Childhood Craniopharyngioma Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/brain/hp/child-cranio-treatment-pdq?cid=eb_govdel
National Cancer Institute

Primary brain tumors, including craniopharyngiomas, are a diverse group of diseases that together constitute the most common solid tumor of childhood. Brain tumors are classified according to histology, but tumor location and extent of spread are important factors that affect treatment and prognosis.

Al Identifies Features of Tumor Cells in High-Risk Ovarian Cancer
http://ascopost.com/News/59644
ASCO Post

Jan 13th, 2019 - Scientists have developed a new test that scans the shapes of tumor cells to select women with especially aggressive ovarian cancer. A team at The Institute of Cancer Research (ICR), London, created an artificial intelligence (AI) tool that looks for clusters of cells within tumors with misshapen nuclei. Findings from the study were published by Heindl et al in Nature Communications.

Direct-Acting Antiviral Therapy not Associated with Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study
https://www.gastrojournal.org/article/S0016-5085(19)30057-5/pdf
Singal,A.,et al

Jan 16th, 2019 - Background & Aims There is controversy over the effects of direct-acting antiviral (DAA) therapies for hepatitis C (HCV) infection on hepatocellular carcinoma (HCC) recurrence and tumor aggressiveness. We compared HCC recurrence patterns between DAA-treated and untreated HCV-infected patients who had achieved a complete response to HCC treatment in a North American cohort.

A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric...
https://meetinglibrary.asco.org/record/169297/abstract
Shah,M.,et al

Jan 16th, 2019 - Andecaliximab (ADX) is a monoclonal antibody that inhibits matrix metalloproteinase 9, an extracellular enzyme involved in matrix remodeling, tumor growth, and metastasis. A phase I/Ib study of mFOLFOX6 + ADX revealed encouraging antitumor activity in patients (pts) with gastric or gastroesophageal junction (GEJ) adenocarcinoma (median first-line, progression-free survival [PFS] of 9.9 months)....

Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
https://www.pnas.org/content/early/2019/01/10/1811067116
Blando,J.,et al

Jan 10th, 2019 - The study demonstrates that V-domain immunoglobulin suppressor of T cell activation (VISTA) is an immune checkpoint that is preferentially expressed at higher levels in pancreatic cancer. The study gives a detailed analysis of immune infiltration in primary and metastatic pancreatic tumors compared with melanoma, which differs in its tumor/stromal distribution. Our data indicate that human panc...

The incidence of leukemia, lymphoma, and multiple myeloma among atomic bomb survivors: 1950 – 2001
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875218/
Radiation Research;

Dec 28th, 2013 - Incident cases used in the analyses presented here were identified by the Leukemia and Tumor/Tissue Registries in Hiroshima and Nagasaki with follow-up through the end of 2001 – 55 years after the bombings and 14 years beyond that used in the previous comprehensive report. Analyses are presented for all leukemias other than chronic lymphocytic leukemia (CLL) or adult T-cell leukemia (ATL) as a ...

Hirsutism in Women
https://www.aafp.org/afp/2019/0801/p168.html

Jul 31st, 2019 - Hirsutism is the excessive growth of terminal hair in a typical male pattern in a female. It is often a sign of excessive androgen levels. Although many conditions can lead to hirsutism, polycystic ovary syndrome and idiopathic hyperandrogenism account for more than 85% of cases. Less common causes include idiopathic hirsutism, nonclassic congenital adrenal hyperplasia, androgen-secreting tumor...

FDA Approves Daiichi Sankyo’s TURALIO™ (pexidartinib) for the Treatment of Select Patients with TGCT, a Rare and Debilitating Tumor
https://dsi.com/press-releases/-/article/364091/10481984

Aug 1st, 2019 - TURALIO is the first and only approved therapy for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery

Recent Trends in the Treatment and Prognosis of Male Breast Cancer
https://ascopost.com/news/october-2019/recent-trends-in-the-treatment-and-prognosis-of-male-breast-cancer/

Oct 8th, 2019 - A recent analysis published by Yadav et al in Cancer reviewed how the treatment of male breast cancer has evolved over the years 2004 to 2014. In addition, certain patient-, tumor-, and treatment-related factors were found to be linked with better survival.

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
https://jnccn.org/view/journals/jnccn/17/12/article-p1529.xml
JNCCN Gilligan T,et al

Nov 30th, 2019 - Testicular cancer is relatively uncommon and accounts for <1% of all male tumors. However, it is the most common solid tumor in men between the ages of 20 and 34 years, and the global incidence has been steadily rising over the past several decades. Several risk factors for testicular cancer have been identified, including personal or family history of testicular cancer and cryptorchidism. Test...

Comprehensive Paired Tumor/Germline Testing for Lynch Syndrome: Bringing Resolution to the Diagnostic Process
http://ascopubs.org/doi/full/10.1200/JCO.18.00696
Salvador,M.,et al

Jan 30th, 2019 - Paired testing identified a cause for MMRd tumors in 76% and 61% of patients without and with prior LS germline testing, respectively. Findings support inclusion of tumor sequencing as well as comprehensive LS germline testing in the LS testing algorithm. Paired testing offers a complete, convenient evaluation for LS with high diagnostic resolution.

FDA Approves the NovoTTF-100L™ System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma
https://www.novocure.com/fda-approves-the-novottf-100ltm-system-in-combination-with-chemotherapy-for-the-treatment-of-malignant-pleural-mesothelioma/

May 22nd, 2019 - Novocure (NASDAQ: NVCR) today announced that the U.S. Food and Drug Administration (FDA) has approved the NovoTTF-100L System in combination with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM). NovoTTF-100L is a non-invasive, antimitotic cancer treatment that delivers Tumor Treating F...

Acute Myeloid Leukemia (AML) Subtypes and Prognostic Factors
https://www.cancer.org/cancer/acute-myeloid-leukemia/detection-diagnosis-staging/how-classified.html

Aug 20th, 2018 - For most types of cancer, determining the stage (extent) of the cancer is very important. The stage is based on the size of the main tumor and how far the cancer has spread. This can be helpful in predicting a person’s outlook and deciding on treatment.

Microenvironmental niche divergence shapes BRCA1-dysregulated ovarian cancer morphological plasticity
https://www.nature.com/articles/s41467-018-06130-3
Heindl,A.,et al

Sep 24th, 2018 - How tumor microenvironmental forces shape plasticity of cancer cell morphology is poorly understood. Here, we conduct automated histology image and spatial statistical analyses in 514 high grade serous ovarian samples to define cancer morphological diversification within the spatial context of the microenvironment. Tumor spatial zones, where cancer cell nuclei diversify in shape, are mapped in ...

Guidelines for Treatment and Monitoring of Adult Survivors of Pediatric Brain Tumors
https://link.springer.com/article/10.1007%2Fs11864-019-0602-0
Janss,A.,et al

Feb 8th, 2019 - Pathologies of pediatric brain tumors are more varied than those diagnosed in adults and survival outcomes more optimistic. Therapies for pediatric brain tumors are also diverse and treatment options are expanding. The growing number of adult survivors of childhood brain tumors is quite diverse. Medical management of these adults requires understanding the tumor diagnosis and location, the moda...

Widely metastatic IDH1-mutant glioblastoma with oligodendroglial features and atypical molecular findings: a case report and review of current challenges in molecular diagnostics
https://diagnosticpathology.biomedcentral.com/articles/10.1186/s13000-019-0793-5
Romo,C.,et al

Feb 8th, 2019 - We present the case of a 28-year-old man with an IDH1 and TP53 mutant high grade glioma with abnormalities in chromosomes 1 and 19 suggestive of anaplastic oligodendroglioma that rapidly progressed to widespread metastatic disease. Biopsy of a liver lesion confirmed metastasis of the patient’s known brain primary and chemotherapy with temozolomide was initiated. The patient’s rapidly growing tu...

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
https://www.nature.com/articles/s41591-018-0337-7
Cloughesy,T.,et al

Feb 10th, 2019 - Glioblastoma is the most common primary malignant brain tumor in adults and is associated with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a randomized, multi-institution clinical trial to evaluate immune responses and survival following neoadjuvant and/or adjuvant therapy with pembrolizumab in 35 patients with recurrent, surgically resectable glioblastoma...